Silmitasertib (CX-4945) Disrupts ERα/HSP90 Interaction and Drives Proteolysis through the Disruption of CK2β Function in Breast Cancer Cells is a research paper published in Cancers (2024). On theSindex it has a DataRank of 0.208. It has been cited 3 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.208
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →NIH
Grant: 2U54MD007595
NIH
Grant: 5SC1GM136562
NIH
Grant: D3400006
NIMHD NIH HHS
Grant: U54 MD007595
NIH HHS
Grant: 5SC1GM136562412-04
NIH HHS
Grant: 2U54MD007595-16
NIGMS NIH HHS
Grant: SC1 GM136562
National Institutes of Health
Grant: 5SC1GM136562-02
Effect of CX4945 in tamoxifen resistant BCa
National Institutes of Health
Grant: 3U54MD007595-14S1
Xavier RCMI Renewal Application-Overall
FWCI
1.15
Citation Percentile
0.8%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals